276 related articles for article (PubMed ID: 35995347)
1. Chronic kidney disease: Which role for xanthine oxidoreductase activity and products?
Polito L; Bortolotti M; Battelli MG; Bolognesi A
Pharmacol Res; 2022 Oct; 184():106407. PubMed ID: 35995347
[TBL] [Abstract][Full Text] [Related]
2. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
Chen C; Lü JM; Yao Q
Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
[TBL] [Abstract][Full Text] [Related]
3. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity.
Furuhashi M
Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E827-E834. PubMed ID: 32893671
[TBL] [Abstract][Full Text] [Related]
4. Xanthine oxidoreductase in atherosclerosis pathogenesis: not only oxidative stress.
Battelli MG; Polito L; Bolognesi A
Atherosclerosis; 2014 Dec; 237(2):562-7. PubMed ID: 25463089
[TBL] [Abstract][Full Text] [Related]
5. The double faced role of xanthine oxidoreductase in cancer.
Chen MM; Meng LH
Acta Pharmacol Sin; 2022 Jul; 43(7):1623-1632. PubMed ID: 34811515
[TBL] [Abstract][Full Text] [Related]
6. Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease.
Nishizawa H; Maeda N; Shimomura I
Hypertens Res; 2022 Apr; 45(4):635-640. PubMed ID: 35046512
[TBL] [Abstract][Full Text] [Related]
7. The role of xanthine oxidoreductase and uric acid in metabolic syndrome.
Battelli MG; Bortolotti M; Polito L; Bolognesi A
Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2557-2565. PubMed ID: 29733945
[TBL] [Abstract][Full Text] [Related]
8. The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors.
Liu N; Xu H; Sun Q; Yu X; Chen W; Wei H; Jiang J; Xu Y; Lu W
Oxid Med Cell Longev; 2021; 2021():1470380. PubMed ID: 33854690
[TBL] [Abstract][Full Text] [Related]
9. Xanthine oxidoreductase and its inhibitors: relevance for gout.
Day RO; Kamel B; Kannangara DR; Williams KM; Graham GG
Clin Sci (Lond); 2016 Dec; 130(23):2167-2180. PubMed ID: 27798228
[TBL] [Abstract][Full Text] [Related]
10. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.
Mallat SG; Al Kattar S; Tanios BY; Jurjus A
Curr Hypertens Rep; 2016 Oct; 18(10):74. PubMed ID: 27696189
[TBL] [Abstract][Full Text] [Related]
11. Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis.
Kimura Y; Tsukui D; Kono H
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830282
[TBL] [Abstract][Full Text] [Related]
12. Xanthine oxidoreductase in cancer: more than a differentiation marker.
Battelli MG; Polito L; Bortolotti M; Bolognesi A
Cancer Med; 2016 Mar; 5(3):546-57. PubMed ID: 26687331
[TBL] [Abstract][Full Text] [Related]
13. Association between Plasma Xanthine Oxidoreductase Activity and the Renal Function in a General Japanese Population: The Tohoku Medical Megabank Community-Based Cohort Study.
Taguchi S; Nasu T; Satoh M; Kotozaki Y; Tanno K; Tanaka F; Asahi K; Ohmomo H; Kikuchi H; Kobayashi T; Morino Y; Shimizu A; Sobue K; Sasaki M
Kidney Blood Press Res; 2022; 47(12):722-728. PubMed ID: 36318900
[TBL] [Abstract][Full Text] [Related]
14. Xanthine oxidoreductase: One enzyme for multiple physiological tasks.
Bortolotti M; Polito L; Battelli MG; Bolognesi A
Redox Biol; 2021 May; 41():101882. PubMed ID: 33578127
[TBL] [Abstract][Full Text] [Related]
15. Xanthine oxidoreductase: A leading actor in cardiovascular disease drama.
Polito L; Bortolotti M; Battelli MG; Bolognesi A
Redox Biol; 2021 Nov; 48():102195. PubMed ID: 34844041
[TBL] [Abstract][Full Text] [Related]
16. Xanthine Oxidoreductase in the Pathogenesis of Endothelial Dysfunction: An Update.
Mudgal R; Singh S
Curr Hypertens Rev; 2024; 20(1):10-22. PubMed ID: 38318826
[TBL] [Abstract][Full Text] [Related]
17. Purine-Induced IFN-γ Promotes Uric Acid Production by Upregulating Xanthine Oxidoreductase Expression.
Wang H; Xie L; Song X; Wang J; Li X; Lin Z; Su T; Liang B; Huang D
Front Immunol; 2022; 13():773001. PubMed ID: 35154100
[TBL] [Abstract][Full Text] [Related]
18. Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection.
Kielstein JT; Pontremoli R; Burnier M
Curr Hypertens Rep; 2020 Oct; 22(12):102. PubMed ID: 33128170
[TBL] [Abstract][Full Text] [Related]
19. Metabolic syndrome and cancer risk: The role of xanthine oxidoreductase.
Battelli MG; Bortolotti M; Polito L; Bolognesi A
Redox Biol; 2019 Feb; 21():101070. PubMed ID: 30576922
[TBL] [Abstract][Full Text] [Related]
20. Independent association of plasma xanthine oxidoreductase activity with hypertension in nondiabetic subjects not using medication.
Furuhashi M; Higashiura Y; Koyama M; Tanaka M; Murase T; Nakamura T; Akari S; Sakai A; Mori K; Ohnishi H; Saitoh S; Shimamoto K; Miura T
Hypertens Res; 2021 Sep; 44(9):1213-1220. PubMed ID: 34117403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
